U.S. antiviral stocks rallied sharply in pre-market trading Monday after a deadly Hantavirus outbreak on a luxury cruise ship spurred investor speculation. Moderna Inc. jumped 7.9 percent, Inovio Pharmaceuticals Inc. gained more than 10 percent, and Alpha Pro Tech Ltd. climbed over 5 percent on the news.
"The hantavirus outbreak is ‘a sentinel event’ that speaks to ‘how well the country is prepared for a disease threat,’" said Dr. Jeanne Marrazzo, chief executive officer of the Infectious Diseases Society of America, in an interview with the Associated Press, highlighting the seriousness of the situation.
The catalyst for the market move was a Hantavirus outbreak on the Hondius, a Dutch-flagged expedition cruise ship. The incident, which began last month, has led to the deaths of three passengers: a 70-year-old Dutch man, his 69-year-old wife, and a German woman. The World Health Organization officially declared it an outbreak on May 2.
This news is causing a short-term speculative rally in the biotech sector, underscoring the market's rapid response to public health scares. The event recalls the beginning of the COVID-19 pandemic, when a similar outbreak on the Diamond Princess cruise ship in 2020 preceded a massive global rally in vaccine and treatment-related stocks.
Health authorities in other countries have so far led the response, with the WHO taking a central role while the U.S. Centers for Disease Control and Prevention has been criticized for its delayed action. Unlike COVID-19, Hantavirus does not spread easily between people, and the CDC has stated the risk to the American public is "extremely low."
American passengers from the vessel are being evacuated to a University of Nebraska quarantine center for evaluation. The situation has drawn investor attention to companies involved in vaccine and antiviral development, creating significant short-term volatility in their stocks.
This article is for informational purposes only and does not constitute investment advice.
